On Wednesday, April 9, as part of Poster Session P12, "Aging, Dementia, and Behavioral Neurology: Alzheimer's Treatment" (11:45 AM - 12:45 PM PT), two posters will be presented on real-world ...

Continued Treatment: On Tuesday, Dec. 2, at 5:05 PM PT and Wednesday, Dec. 3, at 2:40 PM PT, new analyses will be presented on benefits of continued therapy and estimated time savings over 10 years of ...

TOKYO, Jul 22, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's ...

Oral presentations during the "New Perspectives on Alzheimer's Therapeutics" scientific platform session highlight the breadth of lecanemab research, including mechanistic and biomarker insights, ...

BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi) at the Alzheimer's ...

Continued treatment: On Tuesday, Dec. 2, at 5:05 PM PT and Wednesday, Dec. 3, at 2:40 PM PT, new analyses will be presented on benefits of continued therapy and estimated time savings over 10 years of ...

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early Alzheimer's disease, initial findings from the CLARITY AD ...

Real-World Experience: During the poster session on Monday, Dec. 1, at 3:00 PM PT and Tuesday, Dec. 2, at 5:30 PM PT, Poster 055 presents an overview of baseline characteristics and preliminary safety ...

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid, and a ...

STOCKHOLM, Nov. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's ...